Cipla today announced that its wholly-owned subsidiary in United Kingdom, Cipla (EU) (hereinafter together referred as Cipla) will invest an additional EUR 3 million in Ethris GmbH (Ethris), a global leader in delivering mRNAs directly to the respiratory system. This additional investment through a convertible loan will accelerate Cipla's participation in the mRNA space. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
